CD19 and cancer: Additional Phase I clinical studies (NCT05989204 and NCT06287528) were performed in patients with Relapsed or Refractory Acute Lymphoblastic Leukemia to evaluate IL-18 secretion by anti-CD19 CAR T cells engineered to constitutively secrete this cytokine in patients with CD19-positive cancers.